Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu

Bibliography

• SCHLESSINGER J: Cell signaling by receptor tyrosine kinases. Cell (2000) 103(2):211-225.
   PubMed Web of Science ®Google Scholar
• WELLS A: EGF receptor. Int. J. Biochem. Cell Biol. (1999) 31(6):637-643.
   PubMed Web of Science ®Google Scholar
• GUY PM, PLATKO JV, CANTLEY LC, CERIONE RA, CARRAWAY KL III: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA (1994) 91(17):8132-8136.
   PubMed Web of Science ®Google Scholar
• JONES JT, AKITA RW, SLIWKOWSKI MX: Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. (1999) 447(2-3):227-231.
   PubMed Web of Science ®Google Scholar
• GULLICK WJ: The type 1 growth factor receptors and their ligands considered as a complex system. Endocr. Relat. Cancer (2001) 8(2):75-82.
   PubMed Web of Science ®Google Scholar
• CHO HS, MASON K, RAMYAR KX et al.: Structure of the extracellular region of HER2 alone and in complex with the herceptin Fab. Nature (2003) 421(6924):756-760.
   PubMed Web of Science ®Google Scholar
• GARRETT TP, MCKERN NM, LOU M et al.: The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell (2003) 11(2):495-505.
   PubMed Web of Science ®Google Scholar
• ALIMANDI M, ROMANO A, CURIA MC et al.: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene (1995) 10(9):1813-1821.
   PubMed Web of Science ®Google Scholar
• BLENIS J: Signal transduction via the MAP kinases: proceed at your own RSK. Proc. Natl. Acad. Sci. USA (1993) 90(13):5889-5892.
   PubMed Web of Science ®Google Scholar
• BURGERING BM, COFFER PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature (1995) 376(6541):599-602.
   PubMed Web of Science ®Google Scholar
• OLAYIOYE MA, NEVE RM, LANE HA, HYNES NE: The ErbB signaling network: receptor heterodimerization in development and cancer. Embo. J. (2000) 19(13):3159-3167.
   PubMed Web of Science ®Google Scholar
• ZHANG W, LIU HT: MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. (2002) 12(1):9-18.
   PubMed Web of Science ®Google Scholar
• CANTLEY LC: The phosphoinositide 3-kinase pathway. Science (2002) 296(5573):1655-1657.
   PubMed Web of Science ®Google Scholar
• MOSCATELLO DK, HOLGADO-MADRUGA M, EMLET DR, MONTGOMERY RB, WONG AJ: Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem. (1998) 273(1):200-206.
   PubMed Web of Science ®Google Scholar
• HYNES NE, LANE HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer (2005) 5(5):341-354.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, CLARK GM, WONG SG et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, GODOLPHIN W, JONES LA et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244(4905):707-712.
   PubMed Web of Science ®Google Scholar
• KAPITANOVIC S, RADOSEVIC S, KAPITANOVIC M et al.: The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology (1997) 112(4):1103-1113.
   PubMed Web of Science ®Google Scholar
• NAHTA R, ESTEVA FJ: HER-2-targeted therapy: lessons learned and future directions. Clin. Cancer Res. (2003) 9(14):5078-5084.
   PubMed Web of Science ®Google Scholar
• SLIWKOWSKI MX, LOFGREN JA, LEWIS GD et al.: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. (1999) 26(4 Suppl. 12):60-70.
   PubMed Web of Science ®Google Scholar
• DREBIN JA, LINK VC, STERN DF, WEINBERG RA, GREENE MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by mAbs. Cell (1985) 41(3):697-706.
   PubMed Web of Science ®Google Scholar
• IZUMI Y, XU L, DI TOMASO E, FUKUMURA D, JAIN RK: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 416(6878):279-280.
   PubMed Web of Science ®Google Scholar
• PICCART-GEBHART MJ, PROCTER M, LEYLAND-JONES B et al.: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. (2005) 353(16):1659-1672.
   PubMed Web of Science ®Google Scholar
• AGUS DB, AKITA RW, FOX WD et al.: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell (2002) 2(2):127-137.
   PubMed Web of Science ®Google Scholar
• FRANKLIN MC, CAREY KD, VAJDOS FF et al.: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 5(4):317-328.
   PubMed Web of Science ®Google Scholar
• RABINDRAN SK: Antitumor activity of HER-2 inhibitors. Cancer Lett. (2005) 227(1):9-23.
   PubMed Web of Science ®Google Scholar
• MOULDER SL, YAKES FM, MUTHUSWAMY SK et al.: Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. (2001) 61(24):8887-8895.
   PubMed Web of Science ®Google Scholar
• MOASSER MM, BASSO A, AVERBUCH SD, ROSEN N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. (2001) 61(19):7184-7188.
   PubMed Web of Science ®Google Scholar
• ANDERSON NG, AHMAD T, CHAN K, DOBSON R, BUNDRED NJ: ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without ErbB2 overexpression. Int. J. Cancer (2001) 94(6):774-782.
   PubMed Web of Science ®Google Scholar
• ARORA A, SCHOLAR EM: Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. (2005) 315(3):971-979.
   PubMed Web of Science ®Google Scholar
• XIA W, MULLIN RJ, KEITH BR et al.: Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ErbB2 and downstream Erk1/2 and AKT pathways. Oncogene (2002) 21(41):6255-6263.
   PubMed Web of Science ®Google Scholar
• RUSNAK DW, LACKEY K, AFFLECK K et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor- derived cell lines in vitro and in vivo. Mol. Cancer Ther. (2001) 1(2):85-94.
   PubMed Web of Science ®Google Scholar
• BENCE AK, ANDERSON EB, HALEPOTA MA et al.: Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects. Invest. New Drugs (2005) 23(1):39-49.
   PubMed Web of Science ®Google Scholar
• XIA W, LIU LH, HO P, SPECTOR NL: Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene (2004) 23(3):646-653.
   PubMed Web of Science ®Google Scholar
• KONECNY GE, PEGRAM MD, VENKATESAN N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-over- expressing and trastuzumab-treated breast cancer cells. Cancer Res. (2006) 66(3):1630-1639.
   PubMed Web of Science ®Google Scholar
• XIA W, GERARD CM, LIU L et al.: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene (2005) 24(41):6213-6221.
   PubMed Web of Science ®Google Scholar
• GEYER CE, CAMERON D, LINDQUIST D et al.: A Phase III randomized, open-label, international study comparing lapatinib and capecitabine vs capacitabine in women with refractory advanced or metastatic breast cancer (EGF100151). 2006 American Society of Clinical Oncology Annual Meeting. Atlanta, Georgia (2006).
   Google Scholar
• SMAILL JB, PALMER BD, REWCASTLE GW et al.: Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J. Med. Chem. (1999) 42(10):1803-1815.
   PubMed Web of Science ®Google Scholar
• FRY DW, BRIDGES AJ, DENNY WA et al.: Specific, irreversible inactivation of the epidermal growth factor receptor and ErbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA (1998) 95(20):12022-12027.
   PubMed Web of Science ®Google Scholar
• SIMON GR, GARRETT CR, OLSON SC et al.: Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a Phase I pharmacokinetic study. Clin. Cancer Res. (2006) 12(15):4645-4651.
   PubMed Web of Science ®Google Scholar
• GARLAND LL, HIDALGO M, MENDELSON DS et al.: A Phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res. (2006) 12(14 Pt 1):4274-4282.
   PubMed Web of Science ®Google Scholar
• MOMOSE Y, MAEKAWA T, ODAKA H, IKEDA H, SOHDA T: Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. Chem. Pharm. Bull. (Tokyo) (2002) 50(1):100-111.
   PubMed Web of Science ®Google Scholar
• MOMOSE Y, MAEKAWA T, YAMANO T et al.: Novel 5-substituted 2,4-thiazolidine- dione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. J. Med. Chem. (2002) 45(7):1518-1534.
   PubMed Web of Science ®Google Scholar
• SRIDHAR SS, SEYMOUR L, SHEPHERD FA: Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. (2003) 4(7):397-406.
   PubMed Web of Science ®Google Scholar
• NAGASAWA J, MIZOKAMI A, KOSHIDA K et al.: Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int. J. Urol. (2006) 13(5):587-592.
   PubMed Web of Science ®Google Scholar
• GUNDERSEN LL, MALTERUD KE, NEGUSSIE AH et al.: Indolizines as novel potent inhibitors of 15-lipoxygenase. Bioorg. Med. Chem. (2003) 11(24):5409-5415.
   PubMed Web of Science ®Google Scholar
• CHEN Z, KIM SH, BARBOSA SA et al.: Pyrrolopyridazine MEK inhibitors. Bioorg. Med. Chem. Lett (2006) 16(3):628-632.
   PubMed Web of Science ®Google Scholar
• HUNT JT, MITT T, BORZILLERI R et al.: Discovery of the pyrrolo[2,1-f][1,2,4] triazine nucleus as a new kinase inhibitor template. J. Med. Chem. (2004) 47(16):4054-4059.
   PubMed Web of Science ®Google Scholar
• FINK BE, VITE GD, MASTALERZ H et al.: New dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorg. Med. Chem. Lett (2005) 15(21):4774-4779.
   PubMed Web of Science ®Google Scholar
• WONG TW, LEE FY, YU C et al.: Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin. Cancer Res. (2006) 12(20 Pt 1):6186-6193.
   PubMed Web of Science ®Google Scholar
• BORZILLERI RM, ZHENG X, QIAN L et al.: Design, synthesis and evaluation of orally active 4-(2,4-difluoro-5-(methoxy- carbamoyl)phenylamino)pyrrolo[2,1-f] [1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J. Med. Chem. (2005) 48(12):3991-4008.
   PubMed Web of Science ®Google Scholar
• BORZILLERI RM, CAI ZW, ELLIS C et al.: Synthesis and SAR of 4-(3-hydroxy- phenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors. Bioorg. Med. Chem. Lett. (2005) 15(5):1429-1433.
   PubMed Web of Science ®Google Scholar
• TRAXLER PM, FURET P, METT H et al.: 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. (1996) 39(12):2285-2292.
   PubMed Web of Science ®Google Scholar
• TRAXLER P, BOLD G, BUCHDUNGER E et al.: Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. (2001) 21(6):499-512.
   PubMed Web of Science ®Google Scholar
• HOEKSTRA R, DUMEZ H, ESKENS FA et al.: Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. (2005) 11(19 Pt 1):6908-6915.
   PubMed Web of Science ®Google Scholar
• MELLINGHOFF IK, TRAN C, SAWYERS CL: Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. (2002) 62(18):5254-5259.
   PubMed Web of Science ®Google Scholar
• CHANG CH, SCOTT GK, KUO WL et al.: ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. Oncogene (1997) 14(13):1617-1622.
   PubMed Web of Science ®Google Scholar
• LIN YZ, CLINTON GM: A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene (1991) 6(4):639-643.
   PubMed Web of Science ®Google Scholar
• PUPA SM, MENARD S, MORELLI D et al.: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene (1993) 8(11):2917-2923.
   PubMed Web of Science ®Google Scholar
• KANDL H, SEYMOUR L, BEZWODAW R: Soluble c-erbB-2 fragment in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br. J. Cancer (1994) 70(4):739-742.
   PubMed Web of Science ®Google Scholar
• SAEZ R, MOLINA MA, RAMSEY EE et al.: p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. (2006) 12(2):424-431.
   PubMed Web of Science ®Google Scholar
• KERKELA R, GRAZETTE L, YACOBI R et al.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) 12(8):908-916.
   PubMed Web of Science ®Google Scholar